Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%
HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

At a Glance

Live Snapshot
Market Cap$467.87M
EPS-1.4500
P/E Ratio-4.40
Earnings Date08/06/2026

rlmd

Change in Working Capital

Last Annual Value

-3.95M

3-Year CAGR

-11%

5-Year CAGR

-6%

10-Year CAGR

-13%

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Competitors Analysis of Change in Working Capital

RLMD · NASDAQ
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
-3.95M
N/AN/AN/A 
-18.18M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
1.47M
80.1%N/A-25.4%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-22.56M
N/AN/AN/A
13.01M
N/A52.2%N/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
-3.35M
N/AN/AN/A
-8.21M
N/AN/AN/A
-424.00K
N/AN/AN/A
-24.71M
N/AN/AN/A
28.41M
N/A50.9%N/A
-50.40M
N/AN/AN/A
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Fair Value Envelope

RLMD · NASDAQ

Our analysis suggests that RLMD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.38, this represents a potential HIDDEN relative to our calculated worth for Relmada Therapeutics, Inc..

Intrinsic Value
Current Price: $6.38